Company intelligence / Profile preview

RMJ Holdings, LLC

Ownership: Private
Development stage: Phase 3

Overview

RMJ Holdings' lead candidate RMJH-111b, a magnesium-based drug using proprietary inverted micellar nanodroplet technology, has completed Phase II studies showing promising safety and efficacy for essential hypertension. The formulation aims to improve blood pressure control with fewer gastrointestinal side effects compared to standard oral magnesium. The company has FDA agreement on pivotal Phase III trial design.[1][4][8]

Therapeutic areas: Cardiovascular
Modalities: Small molecules (repurposed drugs)Mineral-based therapeutics (magnesium)
Industry: Biotech

Drug pipeline

1 asset

RMJH-111b

Beyond the preview

Go deeper on RMJ Holdings, LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RMJ Holdings, LLC.

Explore the full profile